Brain omega-3 polyunsaturated fatty acids modulate microglia cell number and morphology in response to intracerebroventricular amyloid-β 1-40 in mice by unknown
Hopperton et al. Journal of Neuroinflammation  (2016) 13:257 
DOI 10.1186/s12974-016-0721-5RESEARCH Open AccessBrain omega-3 polyunsaturated fatty acids
modulate microglia cell number and
morphology in response to
intracerebroventricular amyloid-β
1-40 in mice
Kathryn E. Hopperton, Marc-Olivier Trépanier, Vanessa Giuliano and Richard P. Bazinet*Abstract
Background: Neuroinflammation is a proposed mechanism by which Alzheimer’s disease (AD) pathology
potentiates neuronal death and cognitive decline. Consumption of omega-3 polyunsaturated fatty acids (PUFA) is
associated with a decreased risk of AD in human observational studies and exerts protective effects on cognition
and pathology in animal models. These fatty acids and molecules derived from them are known to have anti-
inflammatory and pro-resolving properties, presenting a potential mechanism for these protective effects.
Methods: Here, we explore this mechanism using fat-1 transgenic mice and their wild type littermates weaned onto
either a fish oil diet (high in n-3 PUFA) or a safflower oil diet (negligible n-3 PUFA). The fat-1 mouse carries a transgene
that enables it to convert omega-6 to omega-3 PUFA. At 12 weeks of age, mice underwent intracerebroventricular (icv)
infusion of amyloid-β 1-40. Brains were collected between 1 and 28 days post-icv, and hippocampal microglia,
astrocytes, and degenerating neurons were quantified by immunohistochemistry with epifluorescence microscopy,
while microglia morphology was assessed with confocal microscopy and skeleton analysis.
Results: Fat-1 mice fed with the safflower oil diet and wild type mice fed with the fish oil diet had higher brain DHA in
comparison with the wild type mice fed with the safflower oil diet. Relative to the wild type mice fed with the
safflower oil diet, fat-1 mice exhibited a lower peak in the number of labelled microglia, wild type mice fed with fish oil
had fewer degenerating neurons, and both exhibited alterations in microglia morphology at 10 days post-surgery.
There were no differences in astrocyte number at any time point and no differences in the time course of microglia or
astrocyte activation following infusion of amyloid-β 1-40.
Conclusions: Increasing brain DHA, through either dietary or transgenic means, decreases some elements of the
inflammatory response to amyloid-β in a mouse model of AD. This supports the hypothesis that omega-3 PUFA may
be protective against AD by modulating the immune response to amyloid-β.
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Alzheimer’s disease (AD) is characterized by neuronal
loss, the deposition of amyloid-β plaques, and the hyper-
phosphorylation of intracellular tau proteins, leading to
the formation of neurofibrillary tangles. In addition to
these features, neuroinflammation is increasingly rec-
ognized as a hallmark of AD. Postmortem studies have
detected higher levels of neuroinflammatory markers,
such as astrocytes, microglia, cytokines, or comple-
ment, in the brains of patients with AD than in con-
trols [1–6]. Patients with AD have higher plasma levels
of cytokines, such as interleukin (IL)-6 and IL-1β [7],
than healthy controls, while in patients with mild to
moderate AD, elevation in serum tumor necrosis factor
(TNF)-α is associated with cognitive decline [8]. Posi-
tron emission tomography studies using ligands to the
peripheral benzodiazepine binding receptor (such as
[11C](R)-PK11195), which is thought to label activated
microglia, show higher binding in AD patients than in
controls [9] which co-localizes with binding of [11C]
Pittsburgh compound B (PIB), a marker of fibrillary
amyloid-β [10]. Interestingly, scores on the mini mental
state exam, a measure of cognitive impairment where
lower scores indicate greater impairment, are inversely
correlated with PK11195 binding, but not with uptake of
PIB [10], suggesting an independent effect of inflamma-
tion on cognitive decline. This is supported by studies as-
sociating genetic polymorphisms in various inflammation-
associated genes with AD risk, including polymorphisms
in triggering receptor expressed on myeloid cell (TREM)
2, cluster of differentiation (CD) 33, IL-6, toll-like receptor
(TLR) 4, and IL-1 [11–17].
Elevations in markers of neuroinflammation have also
been identified in animal models of AD, such as higher
levels of IL-1β and chemokine CXCL motif (CXCL) lig-
and 1 in TgCRND8 mice than their wild type littermates
[18] and increases in TNF-α, monocyte chemoattractant
protein (MCP)-1, and microglia in 3xTg mice compared
to controls [19]. In intracerebroventricular (icv) infusion
AD models, in which amyloid-β is injected into the
brains of rodents either acutely or chronically via a
pump, there are elevations in brain cytokines, TNF-α
and IL-1β [20], and glial fibrillary acidic protein
(GFAP) and CD68, markers of astrocytes and micro-
glia, [21] relative to controls. Treatments that de-
crease neuroinflammatory markers in animal models
generally improve behavioral scores and decrease AD
pathology [22–25]. Interestingly, immune activation
has been shown to increase the production of
amyloid-β and the hyperphosphorylation of tau pro-
teins [26] and seems to precede the deposition of
amyloid-β plaques [27], which supports the hypoth-
esis that inflammation is a causal factor in AD devel-
opment (for review, see [28]).Docosahexaenoic acid (DHA), the main omega-3 poly-
unsaturated fatty acid (PUFA) in the brain, may be pro-
tective in AD through several mechanisms (for review,
see [29]). DHA promotes neuronal development and
synaptogenesis through its conversion to synaptamide
(docosahexaenoyl ethanolamide), a member of the endo-
cannabinoid family [30]. DHA also regulates levels of
brain-derived neurotrophic factor [31], which could pro-
tect against neuronal and synaptic loss. DHA and eicosa-
pentaenoic acid (EPA) exert immuno-modulatory effects
and are precursors to a class of bioactive lipid molecules,
referred to as specialized pro-resolving mediators, that
have well-characterized anti-inflammatory and pro-
resolving properties (for review, see [32]). These media-
tors may also exert neuroprotective effects, as neuropro-
tection D1, a specialized pro-resolving mediator derived
from DHA, upregulates the expression of anti-apoptotic
genes such as Bcl-2 [33]. Two studies in postmortem
human brain samples detected lower levels of specialized
pro-resolving mediators, including maresin 1, protectin
D1, and resolvin D5 in the hippocampus [33] and ento-
rhinal cortex [34] of patients with AD relative to con-
trols, suggesting that impairments in resolution of
inflammation may be involved in this disease.
Fish consumption and/or elevated blood levels of
omega-3 PUFA are associated in human observational
studies with a decreased risk of AD and a slower rate of
cognitive decline [35, 36]. A recent meta-analysis of ani-
mal studies identified improvements in amyloid-β plaque
levels, cognition, and neurodegeneration in AD models
with omega-3 PUFA treatment [37]. In contrast, human
intervention studies in AD are generally null [38]; how-
ever, there is some evidence of protection in more mild
forms of the disease [39]. As pathological features of AD
may develop over decades prior to the appearance of
symptoms [40], the discrepancy between the results of
the epidemiologic studies, which are mostly primary pre-
vention, and clinical trials in patients with diagnosed AD
may be explained by: differences in the magnitude of
pathology in these populations, by the possibility of a
critical window for effectiveness of a dietary intervention
or by residual confounding. Six animal studies have mea-
sured an inflammatory outcome in an AD model follow-
ing interventions aimed at increasing brain omega-3
PUFA. These are summarized in Table 1, (updated from
[41]). Two studies fed rats with EPA for 4 weeks and
noted reductions in hippocampal protein levels of inter-
feron (IFN)-γ and IL-1β and increases in peroxisome
proliferator-activated receptor (PPAR)γ compared to
control-fed animals 3 h following icv infusion of
amyloid-β 1-40 [42, 43]. Another two studies used the
same icv model but fed EPA [44] or DHA [45] for
27 days and identified dose-dependent reductions in the
hippocampal mRNA and protein for CD11b, GFAP, IL-
Table 1 Studies examining neuroinflammatory markers in AD models following omega-3 interventions





Minogue (2007) [43] icv aβ 1-40 Rat 125 mg/day EPA vs MUFA × 4 weeks 3 h post-surgery ↓ IFN-γ, IL-1β protein
Lynch (2007) [42] icv aβ 1-40 Rat 125 mg/day EPA vs MUFA × 4 weeks 3 h post-surgery ↓ IL-1β protein
Lebbadi (2014) [46] 3xTg-AD Mouse Fat-1 cross 12 or 20 months old ↓ GFAP,↔iPLA2, cPLA2 protein
Parrott (2015) [47] TgCRND8 Mouse Whole food diet containing salmon,
fruits and vegetables
2.46 mg DHA/g diet
After 7 months feeding ↑ TNF-α mRNA
Wen (2016) [44] icv aβ 1-40 Rat 150 or 300 mg/kg/day EPA × 27 days 13 days post-surgery ↓ CD11b, GFAP, TNF-α, IL-1β
mRNA and protein
Wen (2016) [45] icv aβ 1-40 Rat 300 mg/kg/day DHA-PS or DHA-PC × 27 days 27 days post-surgery ↓ CD11b, GFAP, TNF-α, IL-1β
mRNA and protein
Aβ amyloid-β, CD cluster of differentiation, DHA docosahexaenoic acid, EPA eicosapentaenoic acid, GFAP glial fibrillary acidic protein, icv intracerebroventricular,
IFN interferon, IL interleukin, MUFA monounsaturated fatty acid, PC phosphatidylcholine, PLA phospholipase A, PS phosphatidylserine, TNF tumor necrosis factor
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β relative to rats consuming the control chow. One
study crossed triple transgenic 3xTg-AD mice with fat-1
mice, a transgenic animal expressing an omega-3 desa-
turase gene that allows it to convert omega-6 to omega-
3 fatty acids, and detected lower levels of GFAP protein
in the cortex of 3xTg-AD mice expressing the fat-1 gene
after 18 months [46]. In contrast, Parrott et al. noted a
deterioration in cognitive functioning and an increase in
hippocampal gene expression of TNF-α when TgCRND8
mice were fed a whole food diet containing freeze-dried
powdered fish, fruits, and vegetables [47]. As the diet
contained multiple interventions, it cannot be deter-
mined whether this increase in inflammatory markers is
attributable to the fish feeding [47].
As markers of inflammation are produced dynamically
in response to an insult, with an initial increase in levels
followed by resolution (a return to homeostasis), exam-
ining neuroinflammatory markers over time can be use-
ful to understand how inflammation and its resolution
are affected by omega-3 PUFA. Omega-3 PUFA may
affect neuroinflammation by decreasing the peak in pro-
duction of some markers but not others, or by shifting
the time course of their production in ways that are not
captured by measurements at a single time point [41].
As inflammation in the brain is mainly controlled by a
different set of cells than occur in the periphery, the as-
trocytes and microglia, we set out first to characterize
the time course of the inflammatory response to
amyloid-β 1-40, and then to see how this was affected
by changing brain levels of DHA through a dietary or
transgenic approach. While we identified no effect of
changing brain DHA on astrocytes, we detected a lower
peak in microglia activation in the hippocampus of mice
with elevated brain DHA, along with reductions in
markers of neurodegeneration and alterations in micro-
glia morphology that may be indicative of a less acti-
vated phenotype.Methods
Animals
All animal procedures and husbandry were carried out in
accordance with the Regulations of Animals for Research
Act in Ontario and the Guidelines of the Canadian Council
on Animal Care (2015/16 protocol numbers 20011375 and
20011376). Mice were housed in the University of Toronto
Department of Comparative Medicine animal facility at a
controlled temperature (21 °C) and light cycle (14/10
light/dark), 1–4 per cage with ad libitum access to food
and water.
In the first study, 10-week-old male C57BL/6 mice
were obtained from Charles River Laboratories (Saint
Constant, Quebec, Canada) and were maintained on
standard laboratory chow both during a 2 week
acclimatization period prior to surgery and following
surgery until death.
Mice for the second study were obtained via breeding
in-house from male fat-1 mice provided as a generous
gift by Dr. David Ma (University of Guelph, ON,
Canada). The fat-1 mouse carries a fat-1 transgene from
the roundworm Caenorhabditis elegans, enabling it to
endogenously convert omega-6 to omega-3 PUFA, and
thus attain high tissue levels of omega-3 PUFA on an
omega-3 PUFA deplete diet [48]. C57BL/6 dams were
ordered from Charles River Laboratories at 5–6 weeks
of age and maintained on the low omega-3, 10 % saf-
flower oil (SO) diet for 2 weeks prior to breeding with
fat-1 males. Dams were maintained on the SO diet
throughout the pregnancy and lactation to reduce ma-
ternal transfer of omega-3 PUFA. Fat-1 mice were
weaned onto the SO diet, while the wild type (WT)
offspring were weaned onto either the SO diet or a diet
that contained 8 % safflower oil and 2 % fish oil (FO).
Offspring were maintained on these diets until
12 weeks of age, at which point they underwent icv
surgery and were returned to the same diets after sur-
gery until death.
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Animals were fed one of the three experimental diets de-
pending on the study: standard laboratory chow (Teklad
2018, Envigo, Indianapolis, IN, USA) or one of two diets
modified from the AIN-93G rodent diet: the SO diet,
which contains 10 % safflower oil by weight (SO;
D04092701; Research Diets Inc., New Brunswick, NJ,
USA), or the FO diet which contains 2 % menhaden oil
and 8 % safflower oil (FO; D04092702; Research Diets
Inc.). The fatty acid composition of the chow diet used
in our facility has been reported previously [49] and con-
tains 53 % linoleic acid, 19 % oleic acid, 15 % palmitic
acid, 6 % alpha linolenic acid (ALA), and trace amounts
(<0.5 %) of other fatty acids. Fatty acid composition of
the FO and SO diets was confirmed in triplicate on both
fresh (sampled from a sealed box stored at 4 °C) or
week-old (sampled from hoppers in the animal facility
after at least 1 week at room temperature) pellets.
The main fatty acid species in fresh samples of the
two diets are shown in Table 2. As a percent of fatty
acids, the most abundant fatty acids in the SO diet
are linoleic acid (18:2n-6, 70.7 %), oleic acid (18:1n-9,
15.5 %), palmitic acid (16:0, 8.0 %), and stearic acid
(18:0, 2.9 %). The main fatty acid species of the FO
diet are linoleic acid (59.9 %), oleic acid (13.6 %), pal-
mitic acid (10.3 %), myristic acid (14:0, 2.7 %), EPA
(20:5n-3, 2.6 %), and DHA (22:6n-3, 1.5 %). Neither
diet contained >0.5 % of any other fatty acid not
listed in Table 2, and neither diet’s measured compos-
ition differed from the manufacturer’s product specifi-
cations or what has been measured in our lab
previously [50]. The fatty acid composition of the
fresh and week-old diets also did not differ.Table 2 Fatty acid composition of 10 % safflower oil and 2 %
fish oil, 8 % safflower oil diets












Fatty acid percent compositions are calculated as the percentage of the total
identified fatty acids and are means of triplicate analysis. Other fatty acids are
present at levels <0.5 % of total fatty acids not shown
n.d. not detectedGenotyping
Genotyping was carried out using a method adapted from
Orr et al. [50]. Tails of 2–3-week-old mice were coated
with EMLA analgesic cream (AstraZeneca, Mississauga,
Canada), after which 2–3 mm of the tip of the tail was re-
moved and the wound cauterized. Tails were digested over-
night in a cell lysis buffer (100 mM Tris HCl pH 8.5,
5 mM EDTA, 0.2 % sodium dodecyl sulfate, 200 mM
NaCl) with 0.8 mg/ml proteinase K. Tail debris was pel-
leted (20 min × 15,700 relative centrifugal force (rcf)), and
DNA was precipitated by eluting the supernatant into 1 ml
isopropanol. DNA was pelleted (10 min × 15,700 rcf), and
the supernatant was removed to allow the pellet to dry.
The pellet was then resuspended in ×1 Tris-EDTA buffer.
One −1.5 μl of DNA was used in a PCR reaction with a
commercial mastermix (Thermo Scientific, Waltham, MA,
USA) as per manufacturer’s instructions with the following
PCR conditions: 2 min × 95 °C, 30 cycles × (30 s 94 °C, 30 s
55 °C, 1 min 72 °C), followed by the final elongation step
for 10 min at 72 °C. Resultant 250 base pair bands were vi-
sualized on a 1.5 % agarose gel containing SYBR Safe DNA
Gel Stain (Life Technologies, ThermoScientific, Waltham,
MA, USA) using a UV light box.
Gas chromatography
A separate group of non-surgery mice were killed by
CO2 asphyxiation at 12 weeks of age, and total lipids
were extracted from whole brains using a method
adapted from Folch et al. [51]. Total fatty acids were
measured and quantified as described in detail by our
lab previously [52].
Preparation of amyloid-β 1-40 and 40-1 injections
Amyloid-β 1-40 and a reverse peptide control, amyloid-β
40-1, were obtained from Bachem Biochemicals (H-1194
and H-2972, respectively; Bachem Biochemicals, Bubendorf,
Switzerland). The lyophilized powder was diluted to 1 μg/μl
in sterile 0.1 M phosphate-buffered saline (PBS) and aggre-
gated at 37 °C for 96 h to promote formation of oligomers,
fibrils, and fibers as described previously [20, 21, 53].
Aggregation was confirmed by electron microscopy
(Fig. 1a) by identifying fibrils 100–500 nm long and
smooth in appearance [54, 55]. Treatment and control so-
lutions were aliquoted and stored at −20 °C until use.
Negative-stain transmission electron microscopy
Electron microscopy was conducted according to pub-
lished methods [56]. Briefly, 1 % Pioloform-coated cop-
per grids (Canemco #G300HEX, Canada) were charged
using a glow discharge apparatus (Quorum Technolo-
gies, Laughton, East Sussex, UK) at 0.15 Torr × 15 s,
5 mA, and 2 μl of 1 μg/μl amyloid-β 1-40 in PBS was
loaded for 1 min, wicked to remove large solvent drop-
lets and allowed to air dry. Two microliter of 1 %
Fig. 1 (See legend on next page.)
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Fig. 1 a TEM image of aggregated amyloid-β 1-40, length of 100–500 nm and smooth appearance characteristic of fibers. b Mean ± SEM of iba1-
labelled microglia counts in the CA1, CA2, CA3, and DG of the hippocampus following intracerebroventricular infusion of amyloid-β 1-40, normalized
for the counts following infusion of control peptide (amyloid-β 40-1). c Sample images of the CA3 region of the hippocampus 15 days following
intracerebroventricular infusion of either amyloid-β 1-40 (right) or the control peptide amyloid-β 40-1 (left). d Mean ± SEM of GFAP-labelled astrocyte
counts in the CA1, CA2, CA3, and DG of the hippocampus following intracerebroventricular infusion of amyloid-β 1-40, normalized for the counts
following infusion of control peptide. e Sample images from the CA3 region of the hippocampus 15 days following intracerebroventricular infusion of
either amyloid-β 1-40 (right) or the control peptide amyloid-β 40-1 (left). The top row of images in c and e is enhanced for publication, while the
bottom row of images is the same image in which a threshold was applied to show labelled cells. Different letters denote significant differences
(p < 0.05) by one-way ANOVA followed by Bonferroni post hoc test. CA cornu ammonis, DG dentate gyrus, GFAP glial fibrillary acidic protein, iba1
ionized calcium-binding adapter molecule 1. SEM standard error of the mean TEM transmission electron microscopy
Hopperton et al. Journal of Neuroinflammation  (2016) 13:257 Page 6 of 18phosphotungstic acid were then loaded for 45 s to stain
the grids, then wicked and allowed to air dry under an
incandescent light bulb. Grids were then loaded into a
grid deck and visualized via a transmission electron
microscope (Hitachi H-7000 TEM, Japan) at 75 kV.Intracerebroventricular amyloid-β infusion surgery
Surgeries were conducted as described previously [49].
Mice were anesthetized by isoflurane (induction 3 %,
maintenance 2 %) and the top of head shaved. The head
was secured via ear and teeth bars in a stereotaxic setup
with a digital reader (Stoelting, Wood Dale, IL, USA).
The analgesic Marcaine (Hospira Healthcare Corpor-
ation, Montreal, Québec, Canada) was injected at
1.5 mg/kg subcutaneously at the incision site. After
5 min, the skull was exposed and the digital reader
was calibrated to the bregma. The head was gently
raised or lowered to ensure the skull was level
(<0.1 mm difference in height between bregma and
lambda). A small hole was then drilled −1.0 mm
medial/lateral and −0.5 mm anterior/posterior to
bregma, and a 33-gauge needle was lowered −2.4 mm
dorsal/ventral into the left lateral ventricle. Five
microliter of amyloid-β 1-40 or 40-1 was then infused
at a rate of 1 μl/min via a quintessential stereotaxic
injector (Stoelting). The needle was kept in the ven-
tricle for 25 min post-infusion to ensure treatment
diffusion in the cerebrospinal fluid before being
slowly raised to prevent backflow. The accuracy of
this injection into the lateral ventricle was checked
periodically by injection with Evan’s blue dye. The
hole in the skull was sealed with bone wax (Ethicon,
Somerville, New Jersey, USA) and the scalp sutured
shut. Mice were monitored post-surgery until autono-
mous head movement was recovered and were
housed singly until death. Mice were euthanized at
various time points between 24 h and 28 days post-
surgery. Time points were selected based on previous
work in our lab that found that microglia and astro-
cyte activation following icv lipopolysaccharide (LPS)
began increasing after 24 h (unpublished) and on pre-
liminary experiments described here.Sample preparation and immunohistochemistry
Mice were anesthetized with 250 mg/kg intraperitoneal
avertin and euthanized via transcardiac perfusion with
cold PBS for 3 min, followed by 7 min of 4 % parafor-
maldehyde, infused at a rate of 4 ml/min using a peri-
staltic pump (GE Healthcare, Mississauga, ON,
Canada). Brains were extracted and post-fixed for 24 h
in 4 % paraformaldehyde, followed by dehydration and
storage in a 30 % sucrose solution until sectioning.
Brains were frozen in Cryomatrix sectioning medium
(Thermo Scientific, Waltham, MA, USA) and sliced
into 40 μm sections using a cryostat (Leica, CM 1510S,
Concord, ON). Slices were stored in 0.05 % sodium
azide until analysis.
For immunohistochemistry to visualize astrocytes and
microglia, slices were washed three times for 10 min
each in PBS and quenched for 10 min in 0.5 % sodium
borohydride, followed by another three PBS washes. Sec-
tions were blocked for 2 h in a solution of 10 % normal
goat serum, 0.75 % bovine serum albumin, and 0.1 %
Triton-X in PBS and incubated overnight in antibody so-
lution (2 % normal goat serum, 0.01 % Triton-X in PBS),
with rabbit anti-ionized calcium-binding adapter mol-
ecule 1 (iba1) (Wako Chemicals, Richmond VA, USA)
and mouse anti-GFAP (Antibodies Inc., Davis, CA,
USA) antibodies. Anti-iba1 was diluted to a concentra-
tion of 1:2000 for epifluorescent microscopy and 1:1000
for confocal microscopy, while GFAP was diluted 1:1000
for epifluorescent microscopy and 1:500 for confocal mi-
croscopy. Slices were washed three times in cold PBS, and
then incubated for 1 h in antibody solution with 1:2000
goat anti-rabbit Alexa Fluor 568 and 1:2000 goat anti-
mouse Alexa Fluor 488 (Life Technologies, Burlington,
ON, Canada). Slices were then washed three times in
PBS and mounted onto glass microscope slides in
VECTASHIELD Antifade Mounting Medium with
DAPI (Vector Laboratories, Bulingame, CA, USA) and
coverslipped with #1 type micro cover glasses (VWR
International, Mississauga, ON, Canada).
Fluoro Jade C (FJC; Millipore, Darmstadt, Germany)
immunohistochemistry was used to visualize degenerat-
ing neurons via a method adapted from the manufac-
turer’s specifications. Whole brain coronal sections were
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coated slides (Sigma-Aldrich, Oakville, ON Canada) and
allowed to dry overnight. Slides were then placed in a
staining rack and moved sequentially through the fol-
lowing solutions: dH2O × 1 min, 100 % ethanol × 3 min,
70 % ethanol × 1 min, dH2O × 1 min, 0.06 % potassium
permanganate × 15 min on a shaker, dH2O × 1 min, and
then avoiding light: 0.001 % FJC + 0.2 % Hoescht stain in
0.1 % acetic acid × 30 min followed by 3 × 1 min washes
in dH2O prior to drying overnight in the dark.Epi-fluorescence microscopy and cell counting
Cells were visualized in the hippocampus, stereotaxic co-
ordinates interaural 1.5 to 1.7 and bregma −2.1 to 2.3, in
regions identified by comparison to a mouse brain atlas.
Astrocytes and microglia were visualized in the cornu
ammonis (CA) 1, CA2, CA3, and the dentate gyrus
(DG), while FJC-positive neurons were counted in the
CA1 and DG regions both ipsilateral and contralateral
to the injection site. Cells were visualized (0.83 mm ×
0.66 mm field of view) using epifluorescent microscopy.
Iba1-labelled microglia and GFAP-labelled astrocytes
were counted using Nikon Elements software (NIS-Ele-
ments Basic Research, version 3.1) as described previ-
ously [57] with a ×10 objective. Images were acquired
using automated exposure, and the fluorescence inten-
sity for each image was manually adjusted to fall within
the linear range. Three operations were applied to the
images: ×6 clean, ×4 separate, and ×0 smooth. Counting
in Nikon Elements was performed by an experimenter
(KEH) self-blinded (by randomly assigning slices num-
bers 1, 2, 3…n prior to each immunohistochemistry run)
to the genotype/diet grouping and time point, and all
images in the iba1 channel were counted a second time
for validation by a second experimenter (VG), blinded
by the same method, using ImageJ software by manually
thresholding the image and using the Analyze Particles
plugin with a size exclusion limit of 40 μm2. FJC-positive
neurons in the CA1 and DG regions of the hippocam-
pus were counted manually in three predetermined
150 × 150 μm boxes per image, and scores were vali-
dated in a subset of samples by a second blinded
observer.Confocal microscopy and microglia morphology
As microglia are thought to take on an amoeboid morph-
ology, characterized by fewer, less complex branches and a
larger cell body upon activation, brain sections at baseline
and 10 days post-surgery (a peak point in microglia activa-
tion, Fig. 2) were analyzed by confocal microscopy and
skeleton analysis to assess microglia morphology. Twenty
micrometer z-stacks of CA1, CA3, and DG in both the left
and right hippocampus were acquired at 0.5 μm intervalsusing an AxioObserverZ1 spinning disk confocal
microscope (Zeiss, Oberkochen, Germany) at ×20 ob-
jective. Microglia morphology was measured in all cells
(0.44 mm × 0.25 mm field of view) in each region using
a method adapted from Morrison et al. [58]. As illus-
trated in Fig. 3a, maximum intensity projections for the
Iba1 channel of each image were generated, binarized,
and skeletonized using the Skeletonize 2D/3D plugin in
ImageJ, after which the Analyze Skeleton plugin
(http://imagej.net/AnalyzeSkeleton) was applied with
the lowest intensity voxel prune cycle. This plugin ana-
lyzes the pixels of each skeletonized microglia and cate-
gorizes them based on their relationship to one
another, with pixels with only one neighboring pixel
considered end points, pixels with two neighbors con-
sidered slabs (or in this case, a branch), and pixels with
more than two neighbors considered junction points.
The average branch number (process end points per
cell) and length per cell was recorded for each image
with a voxel size exclusion limit of 150 applied. The ra-
tio of end points to junction points was additionally calcu-
lated to give an indication of branching complexity.
Statistical analysis
Data are expressed as mean ± standard error of the
mean, normalized to control peptide-injected animals
(amyloid-β 40-1) in Fig. 1, or to non-surgery animals of
their treatment group in Figs. 2 and 4. Cell counts for
each hippocampal region were obtained from one slice
per animal in the left, and right sides of 3–5 brains per
treatment per time point were used for the work in the
C57BL/6 mice, and in 6–12 brain samples per treat-
ment/genotype per time point in the work with fat-1
mice and their wild type littermates. One-way analysis of
variance (ANOVA) with a Bonferroni post-test was ap-
plied to evaluate differences by genotype/treatment
group in brain fatty acid composition, FJC counts, and
microglia morphology at 10 days post-icv, while a two-
way ANOVA was used to examine main and interactive
effects of genotype/treatment groups and time, with a
Bonferroni post hoc test applied where there was a sig-
nificant interaction.
Results
Time course of microglia and astrocyte activation
following icv amyloid-β 1-40 or control peptide
We first set out to identify time points at which to
visualize the neuroinflammatory response to amyloid-β
1-40 relative to a control peptide, amyloid-β 40-1. Ag-
gregation of amyloid-β 1-40 was confirmed by electron
microscopy (Fig. 1a) by identifying fibrils 100–500 nm
long and smooth in appearance [54, 55]. Increases in
iba1-labelled microglia were seen in the days following
surgery in all four regions of the hippocampus measured
Fig. 2 (See legend on next page.)
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Fig. 2 a–d Iba1-labelled microglia cell counts (±SEM) normalized to non-surgery counts in the hippocampus regions CA1 (a), CA2 (b), CA3 (c),
and dentate gyrus (d). e Representative images of the CA1 region of wild type mice fed safflower oil (WTSO), fat-1 transgenic mice fed safflower
oil (fat-1), and wild type mice fed fish oil (WTFO) prior to surgery (baseline, top two rows) and at 10 days post intracerebroventricular infusion of
amyloid-β peptide (bottom two rows). The top rows for each time point are images enhanced for contrast and sharpness for publication; bottom
images are the same images in which a threshold was applied to show labelled cells. Two-way ANOVA was applied; significant main effects and
interactions are reported beneath each graph. Different letters denote significantly different bars within a time point (e.g., 10 days post-surgery),
while lines and asterisks indicate overall differences between time points. *p < 0.05, **p < 0.01. CA cornu ammonis, DG dentate gyrus, iba1 ionized
calcium-binding adapter molecule 1. SEM standard error of the mean
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four fields), and counts were significantly different from
24 h at 15 days (CA2, CA3, and DG) and 21 days (CA1,
CA2, and CA3) post-icv. Peak levels of microglia were
approximately 50 % greater in the animals injected with
amyloid-β 1-40 as opposed to the control peptide
injected animals at 15 days post-icv. In all regions,
counts were no longer different from 24 h or the peak
by 28 days following surgery.
Increases in GFAP-labelled astrocytes (Fig. 1d, graph
shown for the mean of four fields) were detected in
the CA1, CA2, and CA3 regions, with a peak at 15 days
post-surgery that was significantly different from 24 h.
In all three regions where this pattern was detected,
no significant difference between the peak and its
baseline was seen by 28 days post-surgery. No signifi-
cant differences were detected between any of the time
points in the DG.
Effect of brain fatty acid composition on time course of
microglia and astrocyte activation
The effect of brain omega-3 PUFA composition on the
neuroinflammatory response to amyloid-β was assessed
in fat-1 mice and their wild type littermates weaned onto
either a 10 % safflower oil diet, containing very low
levels of omega-3 PUFA, or a diet in which 2 % of the
safflower oil was replaced with fish oil. A dietary and a
transgenic approach to increasing brain omega-3 PUFA
was used to account for potential confounding arising
from either off-target effects of the transgene, in the case
of the fat-1 mice, or from changes in other elements of
the diet in the case of the WTFO mice, as adding 2 %
fish oil involves the removal of 2 % safflower oil. Fat-1
and WTFO mice had approximately twofold higher
levels (p < 0.05) of brain DHA as a nanomolar percent
of fatty acids relative to wild type safflower fed (WTSO)
mice (Fig. 5). They also had significantly lower levels of
the omega-6 PUFA: arachidonic acid, docosapentaenoic
acid, and docosatetraenoic acid. As a result, the fat-1
and WTFO mice had a two to threefold lower ratio of
brain omega-6: omega-3 PUFA than WTSO mice.
As earlier experiments showed that the injection of
amyloid-β 1-40 is more potently neuroinflammatory
than the control peptide (Fig. 1), microglia and astrocytecounts were normalized to non-surgery animals for each
diet/genotype group rather than to control peptide-
injected animals for each time point in an effort to re-
duce the number of animals required for this study.
Microglia activation of the mean of both left and right
hippocampus regions CA1, CA2, CA3, and DG peaked
at 10 days post-surgery, and for CA2, CA3, and DG,
were no longer significantly different from baseline
levels by 28 days (Fig. 2a–d). A two-way ANOVA
(genotype/diet × time) returned a significant main effect
of time (p < 0.001) in all four regions with a significant
interaction (p < 0.05). Post hoc analysis of the treatment
effect within each time point showed that fat-1 mice
had a lower peak in iba1-labelled microglia number at
10 days post-surgery than the WTSO mice, while
WTFO mice were not different from either group at
any time in any region. Post hoc analysis of the time ef-
fect showed that microglia counts for the three groups
were significantly higher than baseline levels at 10 days
(CA1, CA2, CA3, and DG) and 15 days (CA1 and DG)
post-icv. Counts remained elevated from baseline at
28 days in the CA1 and elevated compared to 3 days in
the DG. When the highest count rather than the aver-
age of the left and right regions was used for analysis,
the significance of the interaction effect was lost in
CA1 and CA3.
When the mean of GFAP-labelled astrocyte counts in
the left and right hippocampus were analyzed (Fig. 4),
no significant main effects of genotype/diet, time, or in-
teractions were found in CA1, CA2, or DG, while a sig-
nificant main effect of time was identified in CA3 (p <
0.05). When the side with the highest counts was used
for analysis, a significant main effect of time was identi-
fied in the CA1, CA2, and CA3 with no genotype/diet ×
time interaction. The highest levels of astrocyte counts
occurred at 10 and 15 days post-icv, with counts up to
50 % above baseline levels.
Fluoro Jade C cell counts
Degenerating neurons were visualized with FJC immu-
nohistochemistry at 10 days post-icv; the time point at
which a difference between the genotype/treatment
groups in microglia counts was observed. No difference
between the groups was detected in CA1; however,
Fig. 3 (See legend on next page.)
Hopperton et al. Journal of Neuroinflammation  (2016) 13:257 Page 10 of 18
(See figure on previous page.)
Fig. 3 a Schematic illustrating the method for measuring microglia morphology with ImageJ Analyze Skeleton (reproduced in part with permission).
Confocal z-stacks are converted to maximum intensity projections, and then thresholded to create a binary image. Images were converted into 2D
skeletons by the Skeletonize 2D/3D plugin, and pixels were analyzed by the Analyze Skeleton plugin. Pixels with one neighbor (labelled in blue) are
branch end points, pixels with two neighbors (labelled in orange) are branches or slabs, and pixels with three or more neighbors (labelled in pink) are
junctions. Average number of microglia process end points (an indicator of the number of microglia processes) per cell (b–d), average process length
per cell (e–g), and process end points per junction, used here as an indicator of branching complexity (h–j) in the CA1, CA3, and DG. All graphs
represent values at 10 days post-intracerebroventricular infusion of amyloid-β 1-40 normalized for non-surgery values, ±SEM. Different letters denote
significantly different bars (p < 0.05) as determined by one-way ANOVA with Bonferroni post-test. CA cornu ammonis, DG dentate gyrus, WTSO wild
type mice fed safflower oil, fat-1 fat-1 mice fed safflower oil, WTFO wild type mice fed fish oil. SEM standard error of the mean
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rons in the DG compared to the WTSO mice, while fat-
1 mice were not different from either group (Fig. 6).
Microglia morphology
Microglia morphology was investigated to determine
whether the differences in cell counts between the diet/
genotype groups identified at 10 days post-icv were re-
lated to microglia activation. No significant differences
between the groups were identified for the number of
microglia process end points per cell, used here and pre-
viously as an indicator of the number of branches per
cell [58, 59], in the CA1 or DG. Microglia of fat-1 mice
had on average significantly more end points per cell
than the WTSO group, but not the WTFO group in
CA3 (Fig. 3b–d). Relative to WTSO mice, microglia
process length was lower in fat-1 and WTFO mice in
CA1 and CA3, and in WTFO mice alone in DG
(Fig. 3e–g). The number of process end points per junc-
tion was calculated to give an indication of branching
complexity or the number of new branches arising from
branch splitting. Both fat-1 and WTFO mice had signifi-
cantly higher branching complexity following surgery
than the WTSO mice in CA1, CA3, and DG (Fig. 3h–j).
Discussion
Here, we show that the numbers of iba1-labelled micro-
glia and GFAP-labelled astrocytes increase following icv
infusion of amyloid-β 1-40, peaking in C57BL/6 mice be-
tween 15 and 21 days post-surgery, and in fat-1 and wild
type mice at 10 days post-surgery. The inflammatory re-
sponse resolves in most regions examined by 28 days
post-surgery, with cell counts no longer significantly dif-
ferent from baseline levels. There was no effect of the
twofold increase in the brain DHA in the fat-1 or
WTFO mice compared to WTSO mice on astrocyte
counts in the four areas of the hippocampus measured;
however, a reduction in the peak in microglia cell num-
ber at 10 days post-surgery was noted in fat-1, but not
the WTFO mice, compared to the WTSO mice. There
was no effect of this change in omega-3 PUFA on the
time course of microglia or astrocyte activation up to
28 days following surgery.There are some indications that microglia in the
hippocampi of fat-1 and WTFO mice take on a less acti-
vated skeleton structure following icv amyloid-β than
the WTSO mice. As microglia become activated (switch-
ing from a surveillance and neurotrophic role to a
phenotype in which replication, migration, cytokine pro-
duction, and phagocytosis occur), they are thought to
shift from a ramified appearance, with numerous pro-
cesses and a small cell body, to an amoeboid phenotype,
characterized by fewer, shorter processes and a larger
cell body [60]. Fat-1 mice had a smaller reduction in
process end points per cell in CA3 in response to icv
amyloid-β, while both fat-1 and WTFO mice retained
more end points per junction, indicating more branch
splitting. A reduction in process end points with micro-
glia activation has been measured using this same
method previously in both a stroke [58] and an AD [59]
model, while omega-3 PUFA deficiency has previously
been shown to alter markers of microglia activation (M1
and M2) and process motility [61]. Surprisingly, branch
length increased in our model in response to icv
amyloid-β, with greater increases in WTSO mice than in
the other two groups, whereas branch length decreased
with activation in the previous studies using this method
[58, 59]. This unexpected finding could be explained by
retractions of terminal branches, leading pixels that were
initially counted as multiple separate branches con-
nected by junction points to be counted as a single lon-
ger branch, which is supported by the reductions in end
points per junction seen in Fig. 3h–j. Thus, the decrease
in branch length could be indicative of decreased
branching complexity, associated with a more inflamma-
tory phenotype, though this should be examined in other
studies. It should be noted that while skeleton analysis
has benefits of unbiased batch processing and branch
quantification, it does not measure the changes in soma
size or branch thickness that may also occur with micro-
glia activation or dystrophia.
While this study provides evidence for a potential
mechanism that may underlie the protective effects of
omega-3 PUFA in AD that have been observed in hu-
man observational studies [35, 36], animal models [37],
and on cognitive decline in some human clinical trials
Fig. 4 (See legend on next page.)
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Fig. 4 a–d GFAP-labelled astrocyte cell counts (±SEM) normalized to non-surgery counts in the hippocampus regions CA1 (a), CA2 (b), CA3 (c),
and dentate gyrus (DG) (d). e Representative images of the CA1 region of wild type mice fed safflower oil (WTSO), fat-1 transgenic mice fed saf-
flower (fat-1), and wild type mice fed fish oil (WTFO) prior to surgery (baseline, top two rows) and at 10 days post-intracerebroventricular infusion
of amyloid-β peptide (bottom two rows). The top rows for each time point are images enhanced for contrast and sharpness for publication; bot-
tom images are the same images in which a threshold was applied to show labelled cells. Two-way ANOVA applied, where significant main effects
are reported beneath each graph. CA cornu ammonis, DG dentate gyrus, GFAP glial fibrillary acidic protein. SEM standard error of the mean
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AD [39]), there are limitations to the interpretation of
the results. The icv amyloid-β model was selected in-
stead of a transgenic AD model as it allows for the full
dynamic response of microglia and astrocytes to
amyloid-β, including an increase in activation followed
by resolution to baseline levels, to be measured. This
would not be possible with the sustained production of
amyloid-β that occurs in transgenic models, as the glia
would be continually stimulated. This method is, how-
ever, limited in comparison with some transgenic
models in its applicability to AD in humans because it
relies on an acute as opposed to chronic exposure to
amyloid-β and does not take into account the hyper-
phosphorylation of tau proteins.
Another limitation of this work is that increasing brain
DHA via either a dietary or a transgenic approach pro-
portionately reduced brain omega-6 PUFA, resulting in
an altered omega-6:omega-3 ratio. It is possible, there-
fore, that some of the immunemodulatory effects re-
ported here could be attributed to the reduction in
omega-6 PUFA, rather than the increase in omega-3
PUFA. This proportional change in brain omega-6 PUFA
would arise in any intervention aimed at increasing brainFig. 5 Whole brain fatty acid composition (±SEM) of wild type mice fed sa
wild type mice fed fish oil (WTFO). Bars illustrate nanomolar percent of all d
acid and, where significant, followed by a Bonferroni post hoc test. Differen
linolenic acid, LNA linoleic acid, ARA arachidonic acid, EPA eicosapentaenoicomega-3 PUFA, so this confounder does not diminish
the clinical or biological relevance of the findings of this
paper. To our knowledge, no one has yet investigated
the effects of modulating dietary omega-6 PUFA on neu-
roinflammation in an AD model, though lowering diet-
ary linoleic acid has recently been shown to attenuate
the increase in prostaglandin E2, a pro-inflammatory
lipid mediator derived from arachidonic acid, and the ac-
tivity of cyclooxygenase (COX)-2, an enzyme involved in
its synthesis, in response to icv LPS [62].
A difficulty in testing for potential anti-
neuroinflammatory effects of omega-3 PUFA is that, in
addition to modulating inflammation, these fatty acids
are also known to be neuroprotective, decreasing the
magnitude of neurological insult associated with a dis-
ease model. For example, administration of DHA 3 h
after medial cerebral artery occlusion, a model of
stroke, decreases infiltration of microglia/macrophage
lineage cells, but also decreases the volume of the is-
chemic infarct [63]. The reduction in microglia infiltra-
tion in these models could be explained either by a
direct effect of DHA treatment on microglia or as a
lower level response to a smaller injury. The same con-
cerns arise in transgenic models of AD, where DHAfflower oil (WTSO), fat-1 transgenic mice fed safflower oil (fat-1), and
etected fatty acids in the brain. One-way ANOVA applied for each fatty
t letters denote significantly different means, p < 0.05. ALA alpha-
acid, DHA docosahexaenoic acid
DG
Fig. 6 Fluoro Jade C-positive cells (±SEM) in the CA1 (a) and DG (b) regions of the hippocampus. Graphs represent counts (mean of three boxes
per image) at 10 days post-icv amyloid-β 1-40. Representative images of the CA1 (c) and DG (d) of the following: from left to right: LPS-injected
positive control mice, wild type mice fed safflower oil (WTSO), fat-1 transgenic mice fed safflower (fat-1), and wild type mice fed fish oil (WTFO)
mice showing the FJC-positive cells (top) and Hoescht staining (a non-discriminate DNA stain). Images are enhanced for contrast and sharpness
for publication. All graphs represent values at 10 days post-intracerebroventricular infusion of amyloid-β 1-40 normalized for non-surgery values ±SEM.
Different letters denote significant differences (p < 0.05) as determined by one-way ANOVA with Bonferroni post hoc test. CA cornu ammonis, DG dentate
gyrus, WTSO wild type mice fed safflower oil, fat-1 fat-1 mice fed safflower oil, WTFO wild type mice fed fish oil
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cursor protein [64], leading to decreased production of
plaque-forming amyloid-β both in vitro [65] and
in vivo [66]. The icv amyloid-β model used here avoids
some of this confounding by administering exogenous
amyloid-β; however, confounding is not entirely re-
moved because fewer FJC-positive neurons were de-
tected in one region of the hippocampus of WTFO
mice compared to WTSO mice (Fig. 6), indicating less
neuronal degeneration. It is possible then that some of
the differences in microglia cell number and morph-
ology reported here could be explained as a decreased
response to a smaller neurological insult, rather than a
direct effect of brain PUFA on the activation of these
cells. However, because the fat-1 group had the smal-
lest increase in microglia cell number in response to
amyloid-β but the WTFO group had the lowest level of
FJC-positive neurons, these results do not appear to be
directly correlated.
While increasing brain DHA may attenuate the in-
crease in microglia counts and alterations in microglia
morphology in response to icv amyloid-β, it is not
known whether these differences are of a sufficient mag-
nitude to be functionally relevant, and if they are,
whether they would be beneficial in AD. While several
groups have noted improvements in cognition and
neuronal death in association with reductions in in-
flammatory markers, including microglia activation, in
AD [67, 68], this is not consistent across studies. For in-
stance, Michaud et al. noted improvements in amyloid-β
clearance and cognition in a transgenic model of AD in
response to an agonist of the TLR4 receptor, which acti-
vates microglia [69]. Chakrabarty et al. separately overex-
pressed IL-6 [70] and IFN-γ [71] in TgCRND8 mice and
measured lower levels of amyloid-β plaque deposition des-
pite elevations in markers of astrocytes and microglia, sug-
gesting that increases in these cells may in fact be
protective, at least at an early stage in the disease. In con-
trast, omega-3 PUFA, which have been shown here and in
other studies to be anti-inflammatory in AD models
[42, 43], appears to exert protective effects on neuronal
loss, amyloid burden, and cognition [37]. Part of the
discrepancy between these models may be related to
the functional effectiveness of microglia in AD. While
an amoeboid phenotype is classically associated with
microglial activation, it is now known that amyloid-β
contributes to microglial dysfunction, including de-
creased phagocytic capacity, so that microglia in AD
may be phenotypically, but not functionally, activated
[60, 72]. Increasing activation of microglia may be
beneficial acutely in AD models by increasing clearance
of amyloid-β; however, as microglia become dysfunc-
tional due to exposure to amyloid-β, the elevated num-
bers seen in human AD and animal models may insteadcontribute to neuronal death and dysfunction. As
omega-3 PUFA promote amyloid-β phagocytosis by
microglia and increase the expression of phagocytic
markers [34, 73], they may prevent this dysfunction in
microglia activity, allowing microglia to exert beneficial
effects in AD.
In this study, differences in the time course of the
astrocyte and microglia responses to amyloid-β were
noted between the experiments conducted in C57BL/6
mice and the fat-1 strains. Counts for both astrocytes
and microglia were generally lower and peaked later in
the C57BL/6 mice, at 15 and 21 days post-icv, respect-
ively, compared to at 10 days in the fat-1 study. In
addition, there was a main effect of time on astrocyte
number in all four regions of the hippocampus mea-
sured in the study using C57BL/6 mice, while in the ex-
periment using the fat-1 mice, a main effect of time was
evident in CA3 but not CA1, CA2, or DG. Fat-1 mice
have a C57BL/6 and C3H strain background, and previ-
ous work in our lab found that fat-1 progeny are 76 %
genetically similar to C57Bl/6 mice [49]. Therefore, gen-
etic differences between the mice in the two studies
could explain some of these discrepancies. Another pos-
sibility is that dietary differences exerted an effect. The
C57BL/6 mice were maintained on a chow diet contain-
ing 6 % ALA, the precursor to DHA, for the duration of
the experiment while the fat-1 study used a safflower oil
diet containing <1 % ALA. A diet containing 200 mg/
100 g diet of ALA (2–2.5 % of fatty acids on a 10 % fat
diet) is thought to be sufficient to maintain brain DHA
levels [74], so these two studies differ not only in the
DHA content of the diets but also in the sufficiency of
the ALA content to maintain brain DHA levels. A fur-
ther possibility is that experimental differences contrib-
uted to the differences in the results between these two
studies. These experiments were conducted at different
times, and while efforts were made to keep the protocols
consistent, different stocks of reagents (including a new
batch of amyloid-β) and new versions of analysis soft-
ware were used. Thus, caution must be undertaken in
directly comparing the results of the experiments in the
C57BL/6 and fat-1 mice.
Differences were also noted between the fat-1 and
WTFO mice in the microglia response to amyloid-β,
despite these groups having similar brain levels of DHA.
Fat-1 mice had significantly lower numbers of iba1-
labelled microglia 10 days post-surgery than the WTSO
mice, while the WTFO mice were not significantly dif-
ferent from either group. In contrast, WTFO, but not
fat-1, mice had significantly fewer degenerating neurons
following icv amyloid-β than WTSO mice. In the previ-
ous work, from our lab using fat-1 mice and the same
diets, fat-1 mice exhibited enrichment in the brain unes-
terified DHA compared to wild type mice fed with a
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oil diet did not demonstrate this comparative enrich-
ment relative to C57BL/6 mice fed with the safflower oil
diet [49]. In this study, the neuroinflammatory response
to LPS was attenuated in the fat-1 group, but not the
fish oil group compared to safflower fed mice, and this
was attributed to the differences in unesterified DHA
[49]. Unesterified fatty acids are substrates for the syn-
thesis of specialized pro-resolving lipid mediators [29],
so it follows that changes in the unesterified pool may
be more functionally important than changes in the
whole brain. Fat-1 and WTFO mice also differ in the
duration of exposure to omega-3 PUFA and DHA. As
fat-1 mice produce omega-3 PUFA endogenously, they
are exposed to these fatty acids throughout gestation
and growth, while WTFO mice are exposed only after
weaning. Thus, differences between these groups of mice
could also be attributed to early programming of the in-
flammatory response due to exposure to omega-3 PUFA
during critical periods of development. It should be
noted, however, that the direction of effect was always
the same for the fat-1 and WTFO groups and these
groups were never significantly different from one an-
other. This consistency suggests that the inflammation
attenuating effects observed in the fat-1 and WTFO
mice is attributable to the common change in the brain
fatty acid composition that occurred in both groups and
not due to residual confounding by diet or genotype.
Brain fatty acid uptake, turnover, and metabolism could
differ between diet/genotype groups and with surgery, so
lipidomics and fatty acid kinetics in response to inflam-
mation should be investigated in future studies to offer
mechanisms by which changing brain omega-3 PUFA
composition affects neuroinflammation.
Conclusions
Increasing brain omega-3 PUFA, through transgenic,
and to a lesser extent, through dietary means decreased
microglia responses to amyloid-β infusion in a mouse
model of AD, though no effects on astrocyte number, or
the length of time for microglia activation to resolve to
baseline levels were evident. Omega-3 PUFA have been
shown in many human observational and animal studies
to be protective against AD symptoms and pathology,
and this study provides evidence that this may occur
through modulation of neuroinflammation, though fur-
ther work is needed to test this hypothesis directly.
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